The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
Westaway
Susan M
SM
Neurology & GI CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, CM19 5AW, UK. sue.m.westaway@gsk.com
D000700:Analgesics / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002211:Capsaicin / Q000494:pharmacology; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D050916:TRPV Cation Channels / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000502:physiology
D000700:Analgesics; D050916:TRPV Cation Channels; C494484:TRPV1 receptor; D002211:Capsaicin